Payment overview · 2025
General Payments
$2,996.05
124 reported records · 30 companies
Healthcare provider profile · identity verified
Jerzy K Magda, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEW CASTLE, PA · NPI 1366433823
Verified facts
What the public records show
CMS Open Payments records show Jerzy K Magda, MD received $2,996.05 in general payments during 2025 across 124 reported records.
ABBVIE INC. accounted for 11.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 48 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Arexvy, Eliquis, Entresto, Farxiga, Jardiance, Lokelma, Mounjaro, Nurtec Odt, Ozempic, Rexulti, Trelegy Ellipta, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lokelma by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 887 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 469 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 249 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 887 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $334.21 | 11.2% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $326.63 | 10.9% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $263.73 | 8.8% | 15 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $213.77 | 7.1% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $211.09 | 7.0% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $188.03 | 6.3% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $144.79 | 4.8% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $144.67 | 4.8% | 8 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $144.35 | 4.8% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $126.94 | 4.2% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $113.41 | 3.8% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $88.98 | 3.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $78.63 | 2.6% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $75.86 | 2.5% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $69.23 | 2.3% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $69.07 | 2.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $56.68 | 1.9% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $51.56 | 1.7% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.03 | 1.4% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $38.30 | 1.3% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $35.53 | 1.2% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $34.40 | 1.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $23.44 | 0.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.21 | 0.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.09 | 0.7% | 1 | 2025 |
| AppliedVR Inc | Unresolved — no canonical attribution shown | $18.44 | 0.6% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $17.29 | 0.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.97 | 0.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $13.99 | 0.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.73 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,942.51 | 122 |
| Education | $53.54 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $314.35 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $280.06 | 12 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $231.30 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $213.77 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $174.96 | 12 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $145.03 | 9 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $144.35 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $138.79 | 7 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $138.79 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $132.20 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $129.12 | 7 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $126.94 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $124.94 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $124.17 | 3 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $122.90 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $118.64 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $118.64 | 8 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $116.77 | 6 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $113.41 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $108.71 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $105.82 | 2 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $88.98 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $78.63 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $75.86 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $69.23 | 4 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $69.07 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $69.07 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $56.68 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $56.68 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $51.56 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $42.03 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $38.30 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $35.53 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $34.40 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $26.15 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.72 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| RelieVRx Normalized: relievrx |
Device | AppliedVR Inc | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.73 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $12.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 25 | exact normalized | Medicare Part D |
| AREXVY arexvy |
2025 | Arexvy | 2024 | 11 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 887 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 199 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 469 | exact normalized | Medicare Part D |
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 249 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 71 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 167 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
179 | 36 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
137 | 32 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
199 | 35 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
887 | 101 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
167 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
469 | 62 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
71 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
249 | 48 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
71 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
887 | 101 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
59 | 58 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1636 | 343 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1411 | 245 |
| Amlodipine Besylate | Amlodipine Besylate | 1234 | 254 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1037 | 260 |
| Eliquis | Apixaban | 887 | 101 |
| Metformin Hcl | Metformin Hcl | 869 | 192 |
| Furosemide | Furosemide | 849 | 174 |
| Pantoprazole Sodium | Pantoprazole Sodium | 810 | 173 |
| Gabapentin | Gabapentin | 807 | 158 |
| Potassium Chloride | Potassium Chloride | 717 | 125 |
| Omeprazole | Omeprazole | 690 | 126 |
| Tamsulosin Hcl | Tamsulosin Hcl | 688 | 139 |
| Lisinopril | Lisinopril | 591 | 140 |
| Losartan Potassium | Losartan Potassium | 560 | 110 |
| Escitalopram Oxalate | Escitalopram Oxalate | 545 | 114 |
| Metoprolol Succinate | Metoprolol Succinate | 545 | 112 |
| Metoprolol Tartrate | Metoprolol Tartrate | 477 | 82 |
| Jardiance | Empagliflozin | 469 | 62 |
| Sertraline Hcl | Sertraline Hcl | 453 | 91 |
| Hydrochlorothiazide | Hydrochlorothiazide | 417 | 86 |
| Glipizide | Glipizide | 374 | 72 |
| Trazodone Hcl | Trazodone Hcl | 366 | 88 |
| Tramadol Hcl | Tramadol Hcl | 362 | 83 |
| Carvedilol | Carvedilol | 315 | 52 |
| Irbesartan | Irbesartan | 303 | 58 |
| Mirtazapine | Mirtazapine | 296 | 58 |
| Xarelto | Rivaroxaban | 296 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 293 | 61 |
| Spironolactone | Spironolactone | 276 | 59 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 270 | 86 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 266 | 48 |
| Alendronate Sodium | Alendronate Sodium | 265 | 58 |
| Clopidogrel | Clopidogrel Bisulfate | 258 | 57 |
| Ozempic | Semaglutide | 249 | 48 |
| Prednisone | Prednisone | 234 | 117 |
| Atenolol | Atenolol | 233 | 56 |
| Donepezil Hcl | Donepezil Hcl | 233 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 208 | 68 |
| Farxiga | Dapagliflozin Propanediol | 199 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 196 | 48 |
| Famotidine | Famotidine | 189 | 44 |
| Bumetanide | Bumetanide | 187 | 37 |
| Allopurinol | Allopurinol | 185 | 49 |
| Meloxicam | Meloxicam | 184 | 52 |
| Ezetimibe | Ezetimibe | 183 | 37 |
| Simvastatin | Simvastatin | 181 | 46 |
| Lorazepam | Lorazepam | 179 | 51 |
| Synthroid | Levothyroxine Sodium | 179 | 36 |
| Alprazolam | Alprazolam | 172 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 167 | 28 |
| Levetiracetam | Levetiracetam | 157 | 21 |
| Montelukast Sodium | Montelukast Sodium | 157 | 33 |
| Finasteride | Finasteride | 152 | 29 |
| Ibuprofen | Ibuprofen | 150 | 49 |
| Azithromycin | Azithromycin | 141 | 107 |
| Amoxicillin | Amoxicillin | 139 | 121 |
| Myrbetriq | Mirabegron | 137 | 32 |
| Warfarin Sodium | Warfarin Sodium | 135 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 135 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 131 | 61 |
| Pioglitazone Hcl | Pioglitazone Hcl | 129 | 30 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 125 | 28 |
| Metformin Hcl Er | Metformin Hcl | 122 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 120 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 118 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 113 | 36 |
| Doxycycline Hyclate | Doxycycline Hyclate | 111 | 79 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 110 | 90 |
| Januvia | Sitagliptin Phosphate | 108 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 100 | 88 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 100 | 17 |
| Baclofen | Baclofen | 99 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 96 | 21 |
| Naproxen | Naproxen | 95 | 56 |
| Cefuroxime | Cefuroxime Axetil | 92 | 62 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 90 | 22 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 88 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 88 | 17 |
| Buspirone Hcl | Buspirone Hcl | 88 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 87 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 87 | 33 |
| Primidone | Primidone | 86 | 16 |
| Glimepiride | Glimepiride | 82 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 82 | 16 |
| Memantine Hcl | Memantine Hcl | 81 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 28 |
| Clonazepam | Clonazepam | 79 | suppressed |
| Valsartan | Valsartan | 78 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 77 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 77 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 20 |
| Levofloxacin | Levofloxacin | 75 | 62 |
| Celecoxib | Celecoxib | 74 | 23 |
| Nystatin | Nystatin | 74 | 31 |
| Cephalexin | Cephalexin | 73 | 50 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 17 |
| Divalproex Sodium | Divalproex Sodium | 73 | 11 |
| Propranolol Hcl | Propranolol Hcl | 72 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 72 | 13 |
| Aripiprazole | Aripiprazole | 71 | 13 |
| Rexulti | Brexpiprazole | 71 | 11 |
| Methylprednisolone | Methylprednisolone | 70 | 61 |
| Paroxetine Hcl | Paroxetine Hcl | 70 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 69 | 15 |
| Risperidone | Risperidone | 67 | 13 |
| Topiramate | Topiramate | 67 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 65 | 58 |
| Colestipol Hcl | Colestipol Hcl | 64 | 15 |
| Clonidine Hcl | Clonidine Hcl | 62 | 17 |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 62 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 13 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 60 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 59 | 11 |
| Meclizine Hcl | Meclizine Hcl | 59 | 35 |
| Paxlovid | Nirmatrelvir/Ritonavir | 59 | 58 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 58 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 57 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | suppressed |
| Latanoprost | Latanoprost | 57 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 57 | 12 |
| Sucralfate | Sucralfate | 57 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 54 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | suppressed |
| Mounjaro | Tirzepatide | 52 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 51 | 34 |
| Tradjenta | Linagliptin | 51 | suppressed |
| Trulicity | Dulaglutide | 51 | suppressed |
| Bupropion Xl | Bupropion Hcl | 50 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 38 |
| Pregabalin | Pregabalin | 48 | suppressed |
| Entresto | Sacubitril/Valsartan | 47 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 47 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 46 | suppressed |
| Dutasteride | Dutasteride | 45 | suppressed |
| Metolazone | Metolazone | 45 | 12 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 44 | 13 |
| Nifedipine Er | Nifedipine | 44 | suppressed |
| Torsemide | Torsemide | 44 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 43 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 43 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 43 | suppressed |
| Chlorthalidone | Chlorthalidone | 42 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 42 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 41 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 41 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 41 | suppressed |
| Calcitriol | Calcitriol | 40 | suppressed |
| Fluconazole | Fluconazole | 40 | 24 |
| Lactulose | Lactulose | 40 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 40 | 14 |
| Ondansetron Odt | Ondansetron | 40 | 29 |
| Ventolin Hfa | Albuterol Sulfate | 39 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 34 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Linzess | Linaclotide | 37 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | suppressed |
| Glipizide Er | Glipizide | 36 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 35 | suppressed |
| Mupirocin | Mupirocin | 35 | 22 |
| Rivastigmine | Rivastigmine Tartrate | 35 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 34 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 34 | 18 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 33 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 33 | suppressed |
| Colchicine | Colchicine | 33 | 14 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 33 | 11 |
| Digoxin | Digoxin | 33 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 33 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 33 | 11 |
| Methocarbamol | Methocarbamol | 33 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | 17 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 24 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 31 | suppressed |
| Xtampza Er | Oxycodone Myristate | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 30 | suppressed |
| Cyclosporine | Cyclosporine | 30 | suppressed |
| Mirabegron Er | Mirabegron | 30 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 30 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Entacapone | Entacapone | 28 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Klor-Con M10 | Potassium Chloride | 27 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 26 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 26 | suppressed |
| Ibu | Ibuprofen | 26 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 25 | 25 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 25 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 25 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 24 | 15 |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Cilostazol | Cilostazol | 24 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Folic Acid | Folic Acid | 23 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Humalog | Insulin Lispro | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Gemtesa | Vibegron | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Anastrozole | Anastrozole | 20 | suppressed |
| Nyamyc | Nystatin | 20 | 14 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Armour Thyroid | Thyroid,pork | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Trospium Chloride | Trospium Chloride | 18 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 18 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | 11 |
| Ketoconazole | Ketoconazole | 17 | 11 |
| Lokelma | Sodium Zirconium Cyclosilicate | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 11 |
| Estradiol | Estradiol | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | 13 |
| Novolin N | Insulin Nph Human Isophane | 16 | suppressed |
| Repaglinide | Repaglinide | 16 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Tadalafil | Tadalafil | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 14 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Exemestane | Exemestane | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | 12 |
| Nitroglycerin | Nitroglycerin | 12 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Bicalutamide | Bicalutamide | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Ramipril | Ramipril | 11 | suppressed |
| Rhopressa | Netarsudil Mesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,996.05 · 124 records | ABBVIE INC. | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, Auvelity, BREZTRI, BRIXADI, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, ENTRESTO, FARXIGA, Fluad, Flucelvax, GARDASIL 9, GVOKE HYPOPEN, INSPIRE, JARDIANCE, Kerendia, LEQVIO, LOKELMA, M-M-R II, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, RelieVRx, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, YUPELRI, ZEPBOUND, ZORYVE | 22 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error